Overview

The Europe pain management drugs market reached US$ 17.13 billion in 2024 and is expected to reach US$ 33.77 billion by 2033, growing at a CAGR of 7.9% during the forecast period of 2025-2033.

Pain management drugs, also called analgesics, are medications aimed at alleviating pain. These are classified into several categories, which majorly include non-steroidal anti-inflammatory drugs (NSAIDs), opioids, corticosteroids, muscle relaxants, anticonvulsants, etc.

NSAIDs are commonly used for mild to moderate pain and help reduce inflammation. Opioid analgesics, including morphine and oxycodone, are stronger medications prescribed for moderate to severe pain. They act by binding to specific receptors in the brain to block pain perception. Anticonvulsants, antidepressants, and adjuvant analgesics are effective for managing nerve pain and chronic pain syndromes.

Market Dynamics: Drivers & Restraints

Rising Development of Novel Drugs

One of the key drivers for the growth of the pain management drugs market is the rising development of novel drugs. As research and technology advance, pharmaceutical companies are increasingly focusing on creating new and more effective treatments for pain. 

For instance, in February 2025, Haleon launched the 24-hour Voltarol Medicated Plaster in the UK, a topical drug designed to provide long-lasting relief for muscle and joint pain. The plaster contains diclofenac sodium, a well-known anti-inflammatory ingredient, and is aimed at individuals experiencing discomfort from conditions like strains, sprains, and sports injuries. This new offering provides continuous pain relief for up to 24 hours, making it a convenient option for users seeking long-term comfort without the need for frequent reapplication.

Moreover, in February 2025, Algiax Pharmaceuticals announced positive topline data from its Phase 2a clinical trial of AP-325, an innovative treatment for chronic neuropathic pain. AP-325, which works as an allosteric GABAA-receptor modulator, demonstrated promising results by rapidly reducing neuropathic pain and offering long-term benefits. The Phase 2a trial, conducted across multiple European countries (Germany, Spain, the Czech Republic, Belgium, and France), focused on peripheral post-surgical neuropathic pain. A total of 99 participants were enrolled to evaluate AP-325 as a monotherapy for this condition.

Competition from Alternative Pain Management Treatments

Competition from alternative pain management treatments is expected to pose a challenge to the growth of the pain management drugs market. As more patients seek non-pharmacological options, there is a growing shift away from traditional drug treatments. Some of the alternative pain management treatment approaches that are gaining traction over pharmacological options include acupuncture, hypnosis, massage, mindfulness meditation, music-based interventions, spinal manipulation, tai chi, qigong, and yoga. This can affect the overall market growth as more individuals are seeking drug-free treatments with rising awareness about health.

As these alternatives gain popularity, they are expected to limit the demand for traditional pain management drugs, making it essential for pharmaceutical companies to innovate and adapt to meet changing patient preferences and remain competitive in the market.

Other alternative therapies such as massage, chiropractic therapies, therapeutic touch, certain herbal therapies, and dietary approaches are also expected to gain demand in the coming years.

Segment Analysis

The Europe pain management drugs market is segmented based on drug type, indication, mode of prescription, and distribution channel.

Drug Type:

The opioids from the drug type segment are expected to dominate the pain management drugs market with the highest market share

Opioids continue to be the most effective treatment for severe pain, including cancer-related, post-surgical, and neuropathic pain. This category includes medications such as oxycodone, hydrocodone, codeine, morphine, and fentanyl. Despite their efficacy, opioid addiction remains a significant public health challenge. As a result, regulatory agencies in Europe have imposed stricter controls on opioid prescriptions, encouraging the development of alternative pain management therapies.

However, the market faces increasing scrutiny due to concerns over addiction and misuse. In response, pharmaceutical companies are focusing on abuse-deterrent formulations (ADF) and non-opioid pain treatments. Key players in the industry include Purdue Pharma, Teva Pharmaceuticals, and Mallinckrodt Pharmaceuticals. Companies like Pfizer and Collegium Pharmaceutical are also advancing extended-release opioid formulations to enhance pain control while minimizing abuse potential.

Opioids are widely used for multiple pain conditions. Surgical pain also drives significant opioid prescriptions, as 40-50% of post-operative patients require them for pain relief. Additionally, severe trauma pain contributes substantially to opioid usage. Chronic diffuse pain affects 10% to 15% of adults in the general population worldwide, further necessitating opioid-based treatments. Moreover, end-of-life palliative care remains a crucial sector where opioids provide essential relief.

With growing regulatory pressures and increasing concerns over opioid dependency, the industry is shifting toward safer pain management solutions. Future developments will likely balance effective pain relief with reducing the risk of addiction through innovative drug formulations and alternative therapies.

Competitive Landscape

The major Europe players in the pain management drugs market include Bayer AG, Haleon, Grünenthal GmbH, ZAMBON COMPANY S.P.A., Viatris Inc, Pfizer Plc, Kenvue Brands LLC, Adalvo, Mundipharma Ges.m.b.H. and Evotec SE, among others.

Key Developments

  • In August 2024, Saridon, a leading pain relief brand in India, launched 'Saridon Woman, ' a unique period pain solution that offers holistic relief from abdominal cramps, backaches, and headaches, with a #NoPainPeriod campaign promoting life without disruption. 

Why Purchase the Report?

  • Technological Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The Europe pain management drugs market report delivers a detailed analysis with 42 key tables, more than 43 visually impactful figures and 159 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Application & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.